Warfarin News and Research

RSS

Warfarin is a drug that prevents blood from clotting. It belongs to the family of drugs called anticoagulants (blood thinners).

FDA approves Daiichi Sankyo's sNDA for Welchol

Daiichi Sankyo, Inc. (DSI) announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental new drug application (sNDA) for Welchol® (colesevelam HCl) to be used as an adjunct to diet and exercise for the reduction of elevated low-density lipoprotein cholesterol (LDL-C) in boys and postmenarchal girls, 10 to 17 years of age, with heterozygous familial hypercholesterolemia (heFH) alone or in combination with a statin after failing an adequate trial of diet therapy.

7 Oct 2009

The Top 10 Medical Innovations for 2010 announced at Cleveland Clinic Medical Innovation Summit

Cleveland Clinic's Top 10 Medical Innovations for 2010 list features a wide range of new techniques and therapies that are being developed to treat everything from deafness and Parkinson's disease to pneumonia and sleep disorders.

7 Oct 2009

New anticoagulant therapy has fewer side-effects than warfarin

In an article reviewed by F1000 Medicine Faculty Members Robert Ruff, Brian Olshansky and Luis Ruilope, the blood-thinner dabigatran is shown to protect against stroke, blood clotting and major bleeding as effectively as warfarin, but with fewer side effects.

30 Sep 2009

Safety profiles of JANUVIA and JANUMET drugs established through clinical development program

Merck has thoroughly reviewed the safety data for sitagliptin, and sitagliptin was not associated with an increase in the incidence of pancreatitis in preclinical studies or in clinical trials of up to two years in duration with more than 6,000 patients.

28 Sep 2009

European CHMP recommends Merck's JANUVIA and JANUMET as add-on to insulin

Merck & Co., Inc., which operates in many countries as Merck Sharp & Dohme (MSD), has received a positive opinion from the European Medicines Agency’s (EMEA) Committee for Medicinal Products for Human Use (CHMP) for JANUVIA® tablets and JANUMET® tablets recommending their use as add-on to insulin for the treatment of type 2 diabetes.

26 Sep 2009

Influenza patients treated with Tamiflu has higher survival rates

Roche announced today that two new observational studies concluded that influenza patients treated with Tamiflu(R) (oseltamivir phosphate) had significantly higher survival rates than untreated patients.

14 Sep 2009

Warfarin therapy provides substantial protection for elder patients with atrial fibrillation

Warfarin (an oral anticoagulant) therapy for patients with atrial fibrillation - the most common type of significant heart rhythm disorder - appears to be most beneficial for the oldest patients, for those who have had a prior stroke and for patients with multiple risk factors for stroke, according to a new study by Kaiser Permanente and Massachusetts General Hospital researchers.

1 Sep 2009

Clinical trial results of Dabigatran proves its effectiveness for treating atrial fibrillation

Researchers today published promising results for a drug that could lead to a replacement for the very effective but difficult-to-use blood thinner Coumadin (sold generically as Warfarin), currently taken by millions of Americans to reduce their risk of stroke.

31 Aug 2009

RE-LY trial establishes effectiveness of PRADAX in reducing stroke risk in AF patients

Results of the landmark RE-LY(R) Trial (Randomized Evaluation of Long term anticoagulant therapy) demonstrate that atrial fibrillation (AF) patients taking PRADAX(R) (dabigatran etexilate) 150mg twice daily (BID) significantly reduced their risk of stroke and systemic embolism by 34 per cent (p less than 0.001) as compared to patients well-controlled on warfarin, without increasing the risk of major bleeding.

31 Aug 2009

Oral dabigatran etexilate reduces the risk of stroke and systemic embolism

Boehringer Ingelheim today announced data from the landmark RE-LY® study - the largest atrial fibrillation (AF) outcomes trial ever conducted (18,113 patients in 44 countries worldwide) - presented for the first time at the European Society of Cardiology Congress and published online in the New England Journal of Medicine. Results show that dabigatran etexilate 150mg BID significantly reduces the risk of stroke and systemic embolism by 34% (p<0.001) in patients with atrial fibrillation compared to well-controlled warfarin without increasing the risk of major bleeding.

31 Aug 2009

Initial results of the CURRENT-OASIS 7 clinical trial due for release

Today, the OASIS study group will present initial results of the CURRENT-OASIS 7 clinical trial at the European Society of Cardiology congress in Barcelona. Sanofi-aventis and Bristol-Myers Squibb, co-commercialization and co-development partners for PLAVIX(clopidogrel bisulfate), were sponsors of the study.

30 Aug 2009

Blood thinner warfarin may have opposite effects in kidney disease patients on dialysis

The blood thinner warfarin can prevent strokes in most individuals with abnormal heart rhythms, but the drug may have the opposite effect in kidney disease patients on dialysis, according to a study appearing in an upcoming issue of the Journal of the American Society Nephrology (JASN). The results suggest that warfarin should be prescribed with caution in patients with kidney failure.

27 Aug 2009

Phase III RE-LY study results to be presented at the European Society of Cardiology Congress

Results of the Phase III RE-LY(R) (Randomized Evaluation of Long-Term Anticoagulant Therapy, Warfarin, Compared to Dabigatran) study will be presented at the European Society of Cardiology (ESC) Congress in Barcelona on Sunday, Aug. 30. The primary objective of RE-LY was to assess the safety and efficacy of the investigational oral direct thrombin inhibitor, dabigatran etexilate, against the current standard therapy, warfarin, for the prevention of stroke in patients with atrial fibrillation (AF).

26 Aug 2009

Mount Sinai Medical Center physicians pioneer a non-surgical procedure for treating LAA

Physicians at The Mount Sinai Medical Center were the first in the country to perform a non-surgical procedure using sutures to tie off a left atrial appendage (LAA), which is the source of blood clots leading to stroke in patients with atrial fibrillation (AFib). AFib is the most common sustained heart-rhythm disorder in the United States.

24 Aug 2009

Herbal supplements aren't always safe!

Natural doesn’t always mean safe when it comes to herbal supplements, according to the August issue of Mayo Clinic Health Letter.

13 Aug 2009

Aryx Therapeutics reports Q2 2009 financials

ARYx Therapeutics, Inc. (NASDAQ:ARYX) today reported results of operations and provided a general business update for the second quarter ended June 30, 2009.

13 Aug 2009

Discovery of entirely new mechanism that promotes blood clot formation

A Monash-led research team has discovered an entirely new mechanism that promotes blood clot formation - a major breakthrough that will impact on treatment and prevention of heart disease and stroke.

26 May 2009

More patients needed in clinical trials to find treatment for patent foramen ovale (PFO)

The American Heart Association and the American College of Cardiology are calling on doctors to enroll more patients in clinical trials for catheter-based closure of patent foramen ovale (PFO), a condition caused when an opening between the two chambers of the heart fails to close at birth.

12 May 2009

Medicare will not pay for genetic tests to determine best Warfarin dosage, according to proposed decision

CMS will not provide Medicare coverage for a genetic test that physicians can use to determine the proper dosage of the blood thinner drug warfarin, the New York Times reports.

5 May 2009

Voice response system useful for monitoring anticoagulant patients

Interactive voice response systems may help improve monitoring of patients taking anticoagulants such as warfarin while reducing the workload of clinical staff, found a study by Ottawa researchers in CMAJ.

27 Apr 2009

Warfarin News and Research

Further Reading

FDA approves Daiichi Sankyo's sNDA for Welchol

The Top 10 Medical Innovations for 2010 announced at Cleveland Clinic Medical Innovation Summit

New anticoagulant therapy has fewer side-effects than warfarin

Safety profiles of JANUVIA and JANUMET drugs established through clinical development program

European CHMP recommends Merck's JANUVIA and JANUMET as add-on to insulin

Influenza patients treated with Tamiflu has higher survival rates

Warfarin therapy provides substantial protection for elder patients with atrial fibrillation

Clinical trial results of Dabigatran proves its effectiveness for treating atrial fibrillation

RE-LY trial establishes effectiveness of PRADAX in reducing stroke risk in AF patients

Oral dabigatran etexilate reduces the risk of stroke and systemic embolism

Initial results of the CURRENT-OASIS 7 clinical trial due for release

Blood thinner warfarin may have opposite effects in kidney disease patients on dialysis

Phase III RE-LY study results to be presented at the European Society of Cardiology Congress

Mount Sinai Medical Center physicians pioneer a non-surgical procedure for treating LAA

Herbal supplements aren't always safe!

Aryx Therapeutics reports Q2 2009 financials

Discovery of entirely new mechanism that promotes blood clot formation

More patients needed in clinical trials to find treatment for patent foramen ovale (PFO)

Medicare will not pay for genetic tests to determine best Warfarin dosage, according to proposed decision

Voice response system useful for monitoring anticoagulant patients

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News